Clinical Trial

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR advanced colorectal cancer, as well as its impact on gut microbiota and the immune microenvironment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-04; most recent amendment 2026-04-09.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-05-13
Trial Details
NCT Number NCT06865521
Lead Sponsor West China Hospital
Conditions Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
Enrollment 22 participants
Start Date 2025-02-21
Primary Completion 2025-07-10 (estimated)
Study Completion 2027-03-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-13